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Abstract: Innate immunity is critical for host defence against pathogen and environmental challenge
and this involves the production and secretion of immune mediators, such as antimicrobial peptides
and pro-inflammatory cytokines. However, when dysregulated, innate immunity can contribute
to multifactorial diseases, including inflammatory rheumatic disorders, type 2 diabetes, cancer,
neurodegenerative and cardiovascular diseases and even septic shock. During an innate immune
response, antimicrobial peptides and cytokines are trafficked via Rab11 multivesicular endosomes,
and then sorted into Rab11 vesicles for traffic to the plasma membrane and secretion. In this study, a
cyclin-dependent kinase inhibitor CDKI-73 was used to determine its effect on the innate immune
response, based on previously identified targets for this compound. Our results showed that CDKI-73
inhibited the delivery of Rab11 vesicles to the plasma membrane, resulting in the accumulation of
large multivesicular Rab11 endosomes near the cell periphery. In addition to the effect on endosome
delivery, CDKI-73 down-regulated the amount of innate immune cargo, including the antimicrobial
peptide Drosomycin and pro-inflammatory cytokines interleukin-6 (IL-6) and tumour necrosis factor
alpha (TNFα). We concluded that CDKI-73 has the potential to regulate the delivery and secretion of
certain innate immune cargo, which could be used to control inflammation.
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1. Introduction
Innate immunity is the first line of host defence against pathogenic challenge and relies on
immune cell recognition systems that trigger the production and secretion of immune mediators.
If unchecked, the secretion of immune mediators can result in chronic inflammation and this is an
important issue for patients with rheumatoid arthritis, type 2 diabetes, cancer and cardiovascular
disease [1–3]. Inflammatory disorders represent a significant burden to both patients and health care
systems, justifying the development of new therapeutics that can control the innate immune system.
The secretion of immune mediators by innate immune cells, such as macrophages, granulocytes
and mast cells, involves the stepwise delivery of this immune cargo from biosynthetic compartments
through sorting endosomes into specialist secretory vesicles. For example, the newly synthesised
pro-inflammatory cytokines, interleukin-6 (IL-6) and tumour necrosis factor alpha (TNFα), are delivered
Cells 2020, 9, 372; doi:10.3390/cells9020372 www.mdpi.com/journal/cells
Cells 2020, 9, 372 2 of 17
as individual or mixed cargo in post-Golgi vesicles to recycling endosomes for sorting and packaging
into specialist vesicles that are transported to the cell surface for secretion [4,5]. In RAW264.7 murine
macrophages, membrane-bound TNFα and soluble IL-6 exit independently from recycling endosomes
and are distinctly targeted to the cell surface [4]. Consequently, while TNFα is trafficked towards the cell
surface at the site of phagocytic cups [6], the transport of IL-6 is excluded from movement to this site [4],
but is still delivered to the cell surface. Rab GTPases are critically involved in the regulation of this
sequential transport process, with for example, cargo sorting in Rab4/Rab11 recycling endosomes [7]
and traffic to the plasma membrane in small Rab11 vesicles [8]. Rab11-mediated exocytosis has
been reported for various cytokines and antimicrobial peptides, including TNFα [6,9], interferon
gamma [9], IL-10 in mammals [5] and the antimicrobial peptide Drosomycin (Drs) in Drosophila [8].
These Rab4/Rab11-dependent sorting and Rab11-dependent exocytosis pathways represent potential
targets for the development of new therapeutics to control innate immune secretion.
The activity of Rab11 is directly controlled by guanine nucleotide exchange factors (GEFs), which
mediate the exchange from guanosine diphosphate to guanosine triphosphate [10,11], and GTPase
activating proteins (GAPs), which facilitate GTPase activation by catalysing the dephosphorylation
of guanosine triphosphate to guanosine diphosphate [12,13]. For example, Drosophila Crag or
calmodulin-binding protein related to a Rab3 GDP/GTP exchange protein [14], human dual-specific
A-kinase-anchoring protein 2 (D-AKAP2, also known as AKAP10) [15] and Drosophila Pkaap [16]
appear to have GEF activity towards Rab11. Three Rab11 GTPase activating proteins have been
identified, including the Drosophila protein Evi5 [17,18] and domain proteins TBC1D11/GAPCenA [19]
and TBC1D15 [20]. Rab11 activity during vesicle trafficking can also be regulated by the Drosophila
Lyst, also known as Blue cheese [21]. Functional defects in human and mouse LYST (also known
as Chédiak-Higashi/Beige) result in the appearance of large lysosome-related compartments with
impaired secretion and increased susceptibility to infection, while loss of LYST gene causes a severe
immunodeficiency such as Chédiak-Higashi syndrome [22]. Interestingly, depletion of LYST in human
epithelial cells has shown no effect on trafficking of endocytic cargo via retrograde transport, endocytic
degradation or autophagy [23]. The modulation of immune cargo exocytosis and secretion, by targeting
these Rab11 regulatory proteins is an avenue for the development of new therapeutics to control
inflammatory diseases.
Cyclin dependent kinases are involved in the control of transcription for multiple genes [24], and are
potential candidates for the regulation of Rab11 vesicle sorting and the secretion of innate immune cargo.
Here, a specific focus on CDKI-73 (12e) [25], a derivative of n-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine,
was employed based on previously identified targets for this compound, including CDK9 and eukaryotic
translation initiation factor 4E (eIF4E) [26], which control the immune response and inflammation.
The primary screens examining the efficiency of CDKI-73 in controlling an innate immune response
were achieved in the fly Drosophila melanogaster, which has been incorporated into the therapeutic
discovery process for human inflammatory disorders [27]. Unlike mammals, the Drosophila immune
system only exhibits innate immune function. It is mainly mediated by the fat body, the cells of which
are large (high DNA ploidy), with proportionally enlarged intracellular compartments, and haemocytes
(professional macrophages). This provided an ideal system to study the effect of CDKI-73 on endosomes
during an innate immune response. Our results revealed that CDKI-73 prevented the delivery of
Rab11 vesicles to the plasma membrane, resulting in the accumulation of large multivesicular Rab11
endosomes at the cell periphery, and effectively this decreased the level of antimicrobial peptide Drs
and pro-inflammatory cytokine secretion. This effect on innate immune cargo delivery and secretion
was demonstrated in both Drosophila and mammalian macrophages.
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2. Materials and Methods
2.1. Fly Stocks
Fly stocks were maintained in standard medium at 25 ◦C [8]. The yeast GAL4-UAS system was
used for fat body-specific gene expression [28] and transgene expression was driven by CG-GAL4 [29].
UAS-Rab11-GFP transgenic stock was obtained from Markos González-Gaitán (University of Geneva,
Geneva, Switzerland) and Donald F. Ready (Purdue University, West Lafayette, IN, USA). UAS-lystRNAi
transgenic stock was obtained from the Bloomington Drosophila Stock Centre (Indiana University,
Bloomington, IN, USA). Note that Drosophila lyst orthologue used in this study is blue cheese (bchs).
2.2. Natural Bacterial Infection of Drosophila Larvae
Early third instar Drosophila larvae were infected orally with Micrococcus luteus in 5% sucrose
(OD600 ~ 200) for 105 min at 25 ◦C, avoiding temperature stress [8]. Control non-infected larvae were
nurtured with sterile-filtered 5% sucrose for an equal time period.
2.3. Drug Treatment of the Fat Body Tissues
The stock solutions of 3-(5-fluoro-4-(4-methyl-2-(methylamino)thiazol-5-yl)pyrimidin-2-ylamino)
benzenesulfonamide (CDKI-73) [25] and 5,6-dichloro-1-β-d-ribofuranosylbenzimidazole (DRB)
compounds [30] were prepared at 10 mM in DMSO (#D2650, Sigma-Aldrich, St. Louis, MO, USA),
which were diluted in sterile phosphate buffered saline (PBS; #D8537, Sigma-Aldrich, St. Louis, MO,
USA) to a final concentration of 50 nM, 500 nM and 1 µM for CDKI-73 and 100 µM for DRB. The fat
body tissues from late third larval instars (−4 h before puparium formation) were dissected into sterile
PBS, and then transferred to an Eppendorf tube containing 300 µL of either PBS (controls), CDKI-73
at 50 nM, 500 nM and 1 µM or DRB at 100 µM [30]. To analyse the morphological changes in Rab11
endosomes, the fat body tissues were treated with CDKI-73 and DRB for 15 min at room temperature
and then imaged at 15, 30 and 45 min.
To analyse the effect of CDKI-73 on antimicrobial peptide Drs gene expression by quantitative
real-time PCR analysis (qRT-PCR), fat body tissues from infected larvae were incubated in either PBS
(controls) or CDKI-73 compound (500 nM and1 µM) for 30 min at room temperature and then rinsed in
PBS. The fat body tissues were collected, snap frozen on dry ice and stored at −80 ◦C for qRT-PCR.
To determine the inhibitory effect of CDKI-73 treatment on innate immune cargo secretion (Drs-GFP),
fat body tissues from infected late third larval instars were dissected and then treated for 30 min at
room temperature with either PBS (controls), or CDKI-73 at 500 nM or 1 µM. The imaging of these
tissues was done within 45 min.
The effect of CDKI-73 treatment on secretion was evaluated in fat body tissues, but not in
hemolymph. The quantification of secreted protein into the hemolymph wasnot technically possible
due to the extensive coagulation of the insect hemolymph upon exposure to air, making this fluid
non-homogeneous and not suitable for quantification by spectrofluorometry [31,32].
2.4. Drs Gene Expression Analysis
For qRT-PCR analysis, RNA was isolated from the fat body tissue of 30 larvae, using a PureLink®
RNA Mini Kit (#12183018A and #12185010, Ambion, Austin, TX, USA). cDNA was synthesised
using a High Capacity RNA-to-cDNA kit (#4387406, Applied Biosystems, Waltham, MA, USA).
qRT-PCR was performed using Fast SYBR® Green Master Mix kit (#4385616, Applied Biosystems,
Waltham, MA, USA) and a 7500 Fast Real-Time PCR System (Applied Biosystems, Waltham, MA, USA).
Three independent biological samples were analysed for each treatment group; each biological sample
contained fat body tissues collected from 30 larvae. The mRNA expression of genes was normalised
against the endogenous control gene rp49 using the ∆∆CT method. PCR primers were obtained from
GeneWorks (Adelaide, Australia). The primers used for the qRT-PCR included: Drs (CG10810) forward,
5′-GTACTTGTTCGCCCTCTTCG-3′, and reverse, 5′-ATTTAGCATCCTTCGCACCA-3′; and rp49
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(CG7939, used as an endogenous control) forward, 5′-CGAGTTGAACTGCCTTCAAGATGACCA-3′,
reverse 5′-GCTTGGTGCGCTTCTTCACGATCT-3′.
2.5. Live Cell Imaging of the Fat Body Tissues
For ex vivo live cell imaging experiments, the fat body tissues were stained with the plasma
membrane stain CellMask™ Deep Red (#C10046, Invitrogen, Waltham, MA USA), and then attached
to a coverslip using Carbomer 940 based gel (Snowdrift Farm, Teton Valley, ID, USA) [33]. The ex vivo
analysis of fat body tissues was limited to 45 min to preserve tissue integrity [33]. Imaging analysis
was performed using a Zeiss LSM710 NLO confocal microscope, equipped with Argon-gas and 633 nm
solid-state lasers (Zeiss, Germany). Each confocal micrograph represented 1.5 µm thin optical sections.
Image processing was conducted with Adobe Photoshop CS6 (Adobe Systems Inc., San Jose, CA, USA).
2.6. Fat Body Viability Assay
Cellular NAD(P)H-dependent redox activity was measured using CellTiter 96® AQueous
Non-Radioactive Cell Proliferation Assay (MTS) according to the manufacturer’s instruction (#K300-500,
Sapphire Bioscience, Redfern, Australia). Fat body tissues were dissected in PBS from CG-GAL4
> UAS-Rab11-GFP/+ transgenic flies and incubated with either PBS or CDKI-73 compound for 15
min and then transferred to 120 µL of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2
-(4-sulfophenyl)-2H-tetrazolium and phenazine methosulfate in DMEM medium (#D6171,
Sigma-Aldrich, St. Louis, MO, USA) in a 96-well plate. The tissues were allowed to incubate
at room temperature for five hours and the absorbance was then measured at 490 nm using a VICTOR
X™Multilabel Plate Reader (PerkinElmer, Waltham, MA, USA). Data represents the mean ± SEM of
three biological replicates for each group.
2.7. Cell Culture
Human monocytic leukemia THP-1 cells were obtained from the American Type Culture Collection
(Sigma-Aldrich, St. Louis, MO, USA) and maintained in RPMI-1640 medium (#R0883, Sigma-Aldrich,
St. Louis, MO, USA), containing 10% fetal bovine serum (#IVT3008403, In Vitro Technologies, Auckland,
Australia) and 2 mM L-glutamine (#25030-081, Gibco, Waltham, MA, USA) at 37 ◦C and 5% CO2
in a Sanyo MCO-17AI humidified incubator (Sanyo Electric Biomedical Co., Ltd., Osaka, Japan).
The THP-1 cells were cultured in 75 mm2 flasks, and cells (1 × 106 cells/mL) that had been passaged
from two up to five times were used for the experiments. THP-1 monocytes were differentiated into
macrophages in 6-well plates by incubation with 3 mL of RPMI-1640 medium, containing 5 ng/mL
of phorbol 12-myristate 13-acetate (#P8139, Sigma-Aldrich, St. Louis, MO, USA) over 48 h [34].
For lipopolysaccharide (LPS) treatment, the macrophages were washed with PBS and pre-treated with
100 ng/mL of LPS from Escherichia coli 0111: B4 (#L3024, Sigma-Aldrich, St. Louis, MO, USA) in 2 mL of
serum free RPMI-1640 medium for two hours at 37 ◦C and 5% CO2. The supernatants were aspirated
and the macrophages treated with either 100 ng/mL of LPS (controls) or 100 ng/mL of LPS together
with different concentrations of CDKI-73 (50 nM and 100 nM) for four hours at 37 ◦C. The supernatants
were collected and stored at −80 ◦C ready for assaying by ELISA.
2.8. ELISA
The amount of IL-1β, IL-6, IL-8 and TNFα in culture supernatants were determined using an
Inflammatory Cytokine Human 5-Plex Panel for the Luminex® platform, according to the manufacturers
instruction (#LHC0003, Novex®, USA). The fluorescence was determined by Luminex xMAP®
technology (Millipore, Billerica, MA, USA). Data represents the mean ± SEM of three biological
replicates for each group.
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2.9. Immunostaining and Confocal Microscopy
The THP-1 macrophages were fixed and stained according to a previously described protocol [8].
Antibodies for immunofluorescence were mouse monoclonal anti-Rab11 (#610657, BD Transduction
Laboratories™, USA), rabbit polyclonal anti-TNFα (#ab6671, Sapphire Bioscience, Redfern, Australia)
and rabbit polyclonal anti-IL-6 (#ab6672, Sapphire Bioscience, Redfern, Australia). Secondary anti-IgG
antibody conjugates with Cy5 labels were obtained from Jackson Immuno Research Laboratories.
The Alexa Fluor® 488 Phalloidin (#A12379) and Hoechst 33,258 DNA (#H3569) stains were obtained
from Invitrogen, USA. Cell biology analysis was carried out with a minimum of three biological
samples. Imaging analysis was performed using a Zeiss LSM710 NLO confocal microscope, equipped
with Argon-gas and 633 nm solid-state lasers (Zeiss, Germany) and a two-photon Mai-Tai® tunable
Ti:Sapphire femtosecond pulse laser (Spectra-Physics, St. Louis, MO, USA). Each confocal micrograph
represented 1.5 µm thin optical sections. Image processing was conducted with Adobe Photoshop CS6
(Adobe Systems Inc., San Jose, CA, USA).
2.10. Cell Viability Assay
The metabolic activity of THP-1 macrophages was measured using a Resazurin based In Vitro
Toxicology Assay Kit (#TOX-8), according to the manufacturer’s instructions (Sigma-Aldrich, USA).
THP-1 macrophages were seeded in 96-well plates at a density of 6.8 × 105 cells/mL in the absence
or presence of CDKI-73 compound at final concentrations of 50 nM, 100 nM, 500 nM, 1 µM, 10 µM,
50 µM and 100 µM. The Resazurin dye solution was added in an amount equal to 10% of the culture
medium volume. The macrophages were then incubated for four hours at 37 ◦C under 5% CO2.
The fluorescence of resofurin produced by macrophages was measured using an EnVision multi-label
plate reader (PerkinElmer, Beaconsfield, UK) at an excitation wavelength of 560 nm and an emission
wavelength of 590 nm. Data represents the mean ± SEM of four biological replicates for each group.
2.11. Measurements and Statistical Analysis
In Drosophila fat body cells, the number of small (≤1 µm) Rab11 vesicles at the plasma membrane
(30 µm sections) and the size of multivesicular Rab11 endosomes throughout the cells (within 40 µm2
regions of interest (ROI)) were defined using Volocity 6.2.1 software (PerkinElmer, USA). Note that
the size of small Rab11 vesicles was close to the resolution limit of the microscope, and therefore the
slight variations in their morphology could not be precisely determined. The fluorescence intensity
of Drs-GFP in fat body cells (within 50 µm2 ROI) and at the plasma membrane (15 µm x 3 µm ROI)
were also measured using Volocity 6.2.1 software. The total fluorescence intensity was corrected by
subtracting background intensity from the one measured in the ROI. In THP-1 macrophages, the
fluorescence intensity of Cy5 was determined within the cells. The difference between group means
was assessed by one-way analysis of variance (ANOVA), with individual group variance assessed
by a Bartlett’s test. Where the level of significance was p < 0.05, post-hoc tests were performed using
a Tukey’s multiple comparison test (using GraphPad Prism version 6.00 for Windows, GraphPad
Software, San Diego, CA, USA). Data was presented as the mean ± SEM.
3. Results
3.1. CDKI-73 Altered the Morphology of Large Rab11 Endosomes
In control Drosophila fat body cells, Rab11 endosomes were observed as either small vesicles or
larger endosomes that contained Rab11 intraluminal vesicles (multivesicular endosomes; Figure 1a).
The treatment of fat body cells with CDKI-73 did not appear to change the morphology of the small
Rab11 vesicles (≤1 µm; Figure 1a–d), but resulted in a significant increase in their numbers, when
compared to the controls (p < 0.05; Figure S1a). Notably, the size of Rab11 multivesicular endosomes in
fat body cells was significantly increased after CDKI-73 treatment (Figure 1a–d,g; p < 0.0001). This effect
on the size of the Rab11 multivesicular endosomes was evident at different doses of CDKI-73 (50 nM,
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500 nM and 1 µM; Figure 1b–d), with slight differences observed within 30 and 60 min post-treatment
(Figure S1b). As there were no significant differences at each of the time points after incubation, the data
was plotted together representing the overall effect of CDKI-73 treatment on multivesicular endosomes
(Figure 1g,h). The number of Rab11 intraluminal vesicles in these multivesicular endosomes was
significantly increased with 500 nM and 1 µM CDKI-73 treatment, when compared to the untreated
controls (p < 0.0001; Figure 1h). Treatment with 100 µM DRB, a highly selective CDK9 inhibitor, did not
produce the same effect on Rab11 multivesicular endosomes (Figure 1e,g). However, RNAi-mediated
silencing of the lysosomal trafficking regulator gene (lyst) produced an increase in the number of small
Rab11 vesicles (≤1 µm) as well as size of Rab11 multivesicular endosomes (Figure 1f), which was
comparable to CDKI-73 treatment (Figure 1g, Figure S1a). lystRNAi did not result in a significant increase
in the number of Rab11 intralumenal vesicles, when compared to the controls, and was therefore
distinct from the response to 500 nM and 1 µM CDKI-73 treatments (Figure 1h). The morphological
changes to Rab11 multivesicular endosomes did not appear to be due to cytotoxic effects, as the
viability of fat body cells treated with CDKI-73 (50 nM–1 µM) was not significantly different from
controls (Figure S2a). However, at the higher concentration of 10 mM, CDKI-73 treatment significantly
decreased the viability of Drosophila fat body cells (p = 0.03; Figure S2b).
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Figure 1. CDKI-73 treatment alters morphology of Rab11 endosomes. (a) Confocal micrographs of
cross-sections through fat body cells showing Rab11-GFP endosomes. Representative images were
from fat body tissues treated either with PBS (a,f), CDKI-73 at 50 nM (b), 500 nM (c), 1 µM (d) or DRBat
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100 µM (e). Fat body cells were from the following genotypes: CG-CAL4 > UAS-Rab11-GFP/+ (a–e)
and UAS-lystRNAi/+; CG-CAL4 > UAS-Rab11-GFP/+ (f). Arrowheads depict large multivesicular Rab11
endosomes. Scale bars: 10 µm. Histograms showing comparative analysis of the size of multivesicular
Rab11 endosomes (g), and the number of Rab11 intraluminal vesicles per multivesicular Rab11
endosome (h). One-way ANOVA and Tukey’s multiple comparison test showed significant differences
between the means in designated groups (depicted by different letters on the bars, p < 0.0001). Data are
represented as mean ± SEM.
3.2. CDKI-73 Increased Rab11 Tubule Formation and Reduced Rab11 Vesicle Delivery to the Plasma Membrane
In fat body cells treated with CDKI-73 (500 nM), there were frequent fusion events observed for
Rab11 endosomes (Figure 2b), but these events were less evident in control fat body cells (Figure 2a).
These fusion events were not observed in lystRNAi depleted fat body cells (data not shown). In addition,
CDKI-73 caused Rab11 tubular projections from endosomes, which were dynamic and remained
elongated for several seconds (Figure 2b).
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showing Rab11-GFP endosomes. Representative images were from fat body tissues (CG-CAL4 >
UAS-Rab11-GFP/+) treated either with PBS (a) or 500 nM CDKI-73 (b). The acquisition speed was
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The distribution of Rab11 vesicles after CDKI-73 treatment was examined in relation to the plasma
membrane using CellMask™ Deep Red. There were significantly more small (≤1 µm) Rab11 vesicles
(p < 0.0001; Figure 2h) at the plasma membrane in controls (Figure 2c), compared to the fat body
cells treated with CDKI-73 at the concentrations of 50 nM (Figure 2d), 500 nM (Figure 2e) and 1 µM
(Figure 2f). The lystRNAi depleted fat body cells also showed a reduced number of small (≤1 µm) Rab11
vesicles at the plasma membrane (Figure 2g), suggesting a similar effect to that observed for CDKI-73
treatment (Figure 2h).
3.3. CDKI-73 Depleted the Amount of Intracellular Drs During an Innate Immune Response
Treatment of fat body tissues with CDKI-73 at 500 nM and 1 µM produced stronger effect on Rab11
endosomes (Figure 1), and therefore these two concentrations were used to determine the inhibitory
effect of the compound on innate immune cargo secretion. Prior to infection, Drs gene expression was
similar in control and fat body tissues treated for 30 min at room temperature with CDKI-73 (500 nM
and 1 µM). In lystRNAi fat body cells, Drs mRNA was significantly reduced (Figure 3a), when compared
to control and CDKI-73 treatment. Under conditions of oral bacterial challenge, there was a significant
up-regulation of Drs transcription in control, CDKI-73 treated (500 nM and 1 µM) and lystRNAi fat body
cells three hours after infection (Figure 3a). While there was an increase in Drs mRNA in response
to infection in fat body cells (Figure 3a), there was significantly less Drs-GFP detected after CDKI-73
treatment, when compared to the infected controls (p < 0.0001; Figure 3b,c–j). Treatment with 1 µM
CDKI-73 (Figure 3h) appeared to reduce the amount of intracellular Drs-GFP by more than that for
500 nM CDKI-73 (Figure 3i), but considering experimental variation, this reduction was not statistically
significant (Figure 3b). In lystRNAi depleted fat body cells, Drs-GFP was detected, but it had a restricted
distribution, being concentrated in large intracellular compartments (Figure 3j).
To further define the effect of CDKI-73 on innate immune cargo delivery, the localisation of the
antimicrobial peptide Drs-GFP was defined at the plasma membrane of fat body cells before and after
infection (Figure S3a–h). Treatment of fat body tissues with 500 nM (Figure S3f) and 1 µM CDKI-73
(Figure S3g) reduced the amount of Drs-GFP at the cell surface, when compared to the infected controls
(Figure S3e). There was also a reduced amount of Drs-GFP at the surface of fat body cells from
lystRNAi transgenic larvae (Figure S3h). Quantitation confirmed that there was a significant reduction
in Drs-GFP signal at the cell surface after treatment with CDKI-73 at concentrations of 500 nM or 1 µM
and lystRNAi depletion, when compared to the infected control (p < 0.0001; Figure S3i).
3.4. CDKI-73 Modulated the Secretion of Pro-Inflammatory Cytokines
As it was not possible to determine secreted Drs-GFP in the insect hemolymph due to the extensive
coagulation of this fluid, the effect of CDKI-73 treatment was studied on pro-inflammatory cytokines
secreted by human THP-1 macrophages. Secretion of the four key proinflammatory cytokines (i.e.,
IL-1β, IL-6, IL-8 and TNFα), accountable for early stages of the immune response, were analysed
before and after LPS-stimulation of the cells. In the absence of LPS stimulation, treatment with
CDKI-73 at 50 nM and 100 nM had no discernible effect on the secretion of IL-1β (Figure 4a), IL-6
(Figure 4b), IL-8 (Figure 4c) and TNFα (Figure 4d), when compared to controls. The secretion of these
cytokines was increased when macrophages were primed with LPS (Figure 4a–d). CDKI-73 did not
result in a significant reduction in the amount of IL-1β detected in the supernatants of LPS-stimulated
macrophages (Figure 4a). In contrast, IL-6 was reduced by 42–67%, when macrophages were treated
with CDKI-73 (50 nM and 100 nM; p < 0.0001; Figure 4b). IL-8 secretion after LPS treatment was not
significantly down-regulated by CDKI-73, when compared to controls (Figure 4c). The secretion of
TNFα was significantly reduced in LPS-stimulated macrophages, when treated with 100 nM CDKI-73
(p < 0.05; Figure 4d).
Cells 2020, 9, 372 9 of 17
Cells 2020, 9, x 9 of 17 
 
 
Figure 3. CDKI-73 depletes Drs in fat body cells after bacterial challenge. (a) The expression of Drs 
was characterised by qRT-PCR. (b) Histogram showing comparative analysis of intracellular Drs-GFP 
signal in fat body cells. One-way ANOVA and Tukey’s multiple comparison test showed significant 
differences between the means in designated groups (depicted by different letters on the bars in (a) 
and (b), p < 0.0001). Data are represented as mean ± SEM. (c–j) Confocal micrographs showing 
distribution of Drs-GFP (green) in fat body cells. The plasma membrane was outlined by CellMask™ 
Deep Red (red). Representative images were from fat body tissues treated for 30 min either with PBS 
(c, f, g, j), CDKI-73 at 500 nM (d, h) or 1 μM (e, i). Fat body tissues were from non-infected (c–f) and 
infected (Micrococcus luteus) larvae (g–j). Fat body tissues were from the following genotypes: CG-
CAL4 > UAS-Rab11-GFP/+ (c–e, g–i) and UAS-lystRNAi/+; CG-CAL4 > UAS-Rab11-GFP/+ (f, j). Scale bars: 
20 μm. 
3.4. CDKI-73 Modulated the Secretion of Pro-Inflammatory Cytokines 
As it was not possible to determine secreted Drs-GFP in the insect hemolymph due to the 
extensive coagulation of this fluid, the effect of CDKI-73 treatment was studied on pro-inflammatory 
cytokines secreted by human THP-1 macrophages. Secretion of the four key proinflammatory 
cytokines (i.e., IL-1β, IL-6, IL-8 and TNFα), accountable for early stages of the immune response, were 
analysed before and after LPS-stimulation of the cells. In the absence of LPS stimulation, treatment 
with CDKI-73 at 50 nM and 100 nM had no discernible effect on the secretion of IL-1β (Figure 4a), IL-
6 (Figure 4b), IL-8 (Figure 4c) and TNFα (Figure 4d), when compared to controls. The secretion of 
these cytokines was increased when macrophages were primed with LPS (Figure 4a–d). CDKI-73 did 
Figure 3. CDKI-73 depletes Drs in fat body cells after bacterial challenge. (a) The expression of Drs
was characterised by qRT-PCR. (b) Histogram showing comparative analysis of intracellular Drs-GFP
signal in fat body cells. One-way ANOVA and Tukey’s multiple comparison test showed significant
differences between the means in designated groups (depicted by different letters on the bars in (a) and
(b), p < 0.0001). Data are represented as mean ± SEM. (c–j) Confocal micrographs showing distribution
of Drs-GFP (green) in fat body cells. The plasma membrane was outlined by CellMask™ Deep Red
(red). Representative images were from fat body tissues treated for 30 min either with PBS (c,f,g,j),
CDKI-73 at 500 nM (d, h) or 1 µM (e, i). Fat body tissues were from non-infected (c–f) and infected
(Micrococcus luteus) larvae (g–j). Fat body tissues were from the following genotypes: CG-CAL4 >
UAS-Rab11-GFP/+ (c–e, g–i) and UAS-lystRNAi/+; CG-CAL4 > UAS-Rab11-GFP/+ (f, j). Scale bars: 20 µm.
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resulted in a substantial reduction of IL-6 puncta (p < 0.0001; Figure 5e, f, g). While there was a higher 
IL-6 fluorescence intensity in CDKI-73 treated and LPS-stimulated macrophages, when compared to 
non-stimulated cells, this was significantly less than that detected in LPS-stimulated macrophages 
(Figure 5g). In addition, there was a limited amount of TNFα fluorescence in control and 50 nM–100 
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Figure 4. CDKI-73 reduces pro-inflammatory cytokine release by human THP-1 macrophages. (a–d)
Comparative histograms showing the secretion of IL-1β (a), IL-6 (b), IL-8 (c) and TNFα (d) from
lipopolysaccharide (LPS)-stimulated THP-1 macrophages after the addition of CDKI-73 compound.
One-way ANOVA and Tukey’s multiple comparison test showed significant differences between the
means in designated groups (depicted by different letters on the bars, p < 0.0001). Data are represented
as mean ± SEM.
To evaluate the effect of CDKI-73 treatment on the in ate immune cargo, the intracellular
distribution of IL-6 and TNFα was investigated in non-stimulated and LPS-stimulated THP-1
macrophages. e secrete le els of these t o cytokines were significantly reduced, and so their
intracellular distribution was further analysed in this study. Prior to LPS-stimulation, there was only
a relatively small amount of IL-6 detected in control (Figure 5a) and CDKI-73 treated macrophages
(Figure 5b,c). Upon stimulation with LPS, there were numerous IL-6 puncta with a widespread
distribution throughout the cytoplasm of control macrophages (Fi ure 5d). CDKI-73 treatment resulted
in a substantial reduction of IL-6 puncta (p < 0.0001; Figure 5e,f,g). While there was a higher IL-6
fluorescence i tensity in CDKI-73 treated and LPS-stimulated macrophages, when compared to
non-stimulated cells, this was significantly less than that detected in LPS-stimulated macrophages
(Figure 5g). In ad ition, there was a limited amount of TNFα fluorescence in co trol and 50 nM–100 nM
CDKI-73 treated macrophages (Fi ure 6a–c). Upon stimulation with LPS, t ere was a dramatic increase
in TNFα fluorescence in co trol THP-1 macrophages (Figure 6d), but not in CDKI-73 treated cells
(p < 0.0001; Figure 6e,f,g).
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Figure 5. CDKI-73 depletes interleukin-6 (IL-6) in LPS-stimulated THP-1 macrophages. (a–f) Confocal
micrographs showing IL-6 detected with anti-IL-6 antibody (red) in relation to the plasma membrane
outlined with Alexa Fluor® 488 Phalloidin (green). The nucleus was depicted by staining with Hoechst
33,258 DNA stain (blue). Representative images were from control THP-1 macrophages (a,d) and THP-1
macrophages treated either with CDKI-73 at 50 nM (b,e) or 100 nM (c,f) for four hours. The visualised
macrophages were non-stimulated (a–c) and LPS-stimulated for six hours (d–f). Scale bars: 20 µm.
(g) Histogram showing comparative analysis of IL-6-Cy5 signal in the designated samples. One-way
ANOVA and Tukey’s multiple comparison test showed significant differences between the means
in designated groups (depicted by different letters on the bars, p < 0.0001). Data are represented as
mean ± SEM.
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test showed significant differences between the means in designated groups (depicted by different 
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(Figures 4a–d,5a,6a,). The pro-inflammatory cytokines IL-6 (Figure S4a) and TNFα (Figure S4b) 
appeared to be associated with Rab11 endosomes in LPS-stimulated THP-1 macrophages (Figure 
S4c). 
In control THP-1 macrophages (Figure 7a), Rab11 endosomes appeared to be less concentrated 
in the perinuclear region than in the same region of THP-1 macrophages treated with 50 nM–1 µM 
CDKI-73 (Figure 7b–e). Consequently, THP-1 macrophages treated with CDKI-73 had fewer Rab11 
vesicles located near the cell surface (Figure 7d, e), when compared to controls (Figure 7a). Treatment 
with 1 µM CDKI-73 (Figure 7e) led to nuclear morphological changes, including nuclear 
fragmentation and chromatin condensation, when compared to both controls (Figure 7a) and lower 
concentrations of CDKI-73 (50 nM–500 nM; Figure 7b–d). However, treatment with CDKI-73 at 50 
nM–1 µM did not appear to be cytotoxic as the viability of THP-1 macrophages was not significantly 
Figure 6. CDKI-73 depletes tumour necrosis factor alpha (TNFα) in LPS-stimulated THP-1 macrophages.
(a–f) Confocal micrographs showing TNFα detected with anti-TNFα antibody (red) in relation to the
plasma membrane outlined with Alexa Fluor® 488 Phalloidin (green). The nucleus was depicted
by staining with Hoechst 33,258 DNA stain (blue). Representative images were from control THP-1
macrophages (a,d), and THP-1 macrophages treated either with CDKI-73 at 50 nM (b,e) or 100 nM
(c,f) for four hours. The visualised macrophages were non-stimulated (a–c) and LPS-stimulated
for six hours (d–f). Scale bars: 20 µm. (g) Histogram showing comparative analysis of TNFα-Cy5
signal in the designated samples. One-way ANOVA and Tukey’s multiple comparison test showed
significant differences between the means in designated groups (depicted by different letters on the
bars, p < 0.0001). Data are represented as mean ± SEM.
3.5. CDKI-73 Altered the Intracellular Distribution of Rab11 Vesicles in Human Macrophages
Pro-inflammatory cytokines can traffic through recycling endosomes and so their intracellular
localisation was compared to Rab11 endosomes. This was examined in LPS-stimulated human
THP-1 macrophages as the basal levels of pro-inflammatory cytokines in non-stimulated cells are
low (Figure 4a–d, Figures 5a and 6a). The pro-inflammatory cytokines IL-6 (Figure S4a) and TNFα
(Figure S4b) appeared to be associated with Rab11 endosomes in LPS-stimulated THP-1 macrophages
(Figure S4c).
In control THP-1 macrophages (Figure 7a), Rab11 endosomes appeared to be less concentrated
in the perinuclear region than in the same region of THP-1 macrophages treated with 50 nM–1 µM
CDKI-73 (Figure 7b–e). Consequently, THP-1 macrophages treated with CDKI-73 had fewer Rab11
vesicles located near the cell surface (Figure 7d,e), when compared to controls (Figure 7a). Treatment
with 1 µM CDKI-73 (Figure 7e) led to nuclear morphological changes, including nuclear fragmentation
and chromatin condensation, when compared to both controls (Figure 7a) and lower concentrations
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of CDKI-73 (50 nM–500 nM; Figure 7b–d). However, treatment with CDKI-73 at 50 nM–1 µM did
not appear to be cytotoxic as the viability of THP-1 macrophages was not significantly different from
controls (Figure 7f). In contrast, at the higher concentrations of CDKI-73 (10 µM, 50 µM and 100 µM),
the viability of THP-1 macrophages was significantly reduced (p < 0.0001; Figure 7f).
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once treatment has ceased. There is therefore a critical need to develop new therapeutics that enable 
effective control of the release of inflammatory immune mediators. Here, we have investigated a CDK 
inhibitor CDKI-73 for potential drug development to control the secretion of inflammatory cytokines. 
Following infection with bacteria, the TLR4/MD-2 complex triggers the initiation of down-
stream signalling events, resulting in the translocation of transcription factors from the cytoplasm 
into the nucleus [35]. For example, NF-κB and interferon regulatory factors can induce the 
transcription of multiple genes involved in antimicrobial defence, including antimicrobial peptides 
and pro-inflammatory cytokines [36,37]. The transcription factor NF-κB can interact with 
CDK9/cyclin T, the catalytic subunit of positive transcription elongation factor P-TEFb [38–40] and 
can be recruited to the IL-8 promoter in TNFα-treated cells [41]. In addition, the interaction of CDK9 
Figure 7. CDKI-73 causes accumulation of Rab11 endosomes in the perinuclear region of THP-1
macrophages. (a–e) Confocal micrographs showing Rab11 endosomes detected with anti-Rab11
antibody (red) in relation to the cell surface, detected by phase-contrast microscopy. The nucleus was
depicted by staining with Hoechst 33,258 DNA stain (blue). Representative images were from control
macrophages (a) and acrophages treated either with CDKI-73 at 50 nM CDKI-73 (b), 100 nM (c),
500 nM (d) or 1 µM (e) for four hours. Arrowheads depict Rab11 vesicles with altered distribution
within the cell. Scale bars: 20 µm. (f) Histogram showing the levels of metabolic activity/redox state of
macrophages after treatment with CDKI-73. One-way ANOVA and Dunnett’s multiple comparison test
showed significa t differences between the means in designated groups (depicte by different letters
on the bars, p < 0.0001). Data are represented as mean ± SEM.
4. iscussion
Inflammatory disorders cause a significant burden to both patients and health care syste s.
Although fast-acting sympto atic drugs (non-steroidal anti-inflammatory drugs and glucocorticoids),
slow-acting disease modifying anti-rheumatic drugs (methotrexate and cytostatic drugs) and
immune-suppressants (calcineurin inhibitors, neutralisers of TNFα and IL-1) have provided some
treatment options, patients often respond poorly to these drugs or the disease recurs once treatment
has ceased. There is therefore a critical need to develop new therapeutics that enable effective control of
the release of inflammatory immune mediators. Here, we have investigated a CDK inhibitor CDKI-73
for potential drug development to control the secretion of inflammatory cytokines.
Following infection with bacteria, the TLR4/MD-2 complex triggers the initiation of down-stream
signalling events, resulting in the translocation of transcription factors from the cytoplasm into the
nucleus [35]. For example, NF-κB and interferon regulatory factors can induce the transcription of
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multiple genes involved in antimicrobial defence, including antimicrobial peptides and pro-inflammatory
cytokines [36,37]. The transcription factor NF-κB can interact with CDK9/cyclin T, the catalytic subunit
of positive transcription elongation factor P-TEFb [38–40] and can be recruited to the IL-8 promoter
in TNFα-treated cells [41]. In addition, the interaction of CDK9 with the IL-6 receptor suggests a
role of CDK9 in signal transduction during an immune response [42,43]. Indeed, the CDK9 inhibitor
flavopiridol can disrupt the transcriptional elongation of gamma fibrinogen gene without affecting
STAT3 (signal transducer and activator of transcription 3) activation or complex formation with
CDK9 [44]. In the current study, following treatment with CDKI-73, there was normal activation of
NF-κB immune response pathways, resulting in gene expression of the antimicrobial peptide Drs,
suggesting that this compound did not alter gene transcription. Given that CDKI-73 has previously
been implicated in the control of eIF4E-mediated translation in cancer cells and had an effect on immune
response [26], it was postulated that CDKI-73 might be acting on either translation, intracellular traffic
or the secretion of immune mediators in Drosophila fat body tissues.
CDKI-73 decreases the phosphorylation of eIF4E by blocking MAPK-interacting kinase (Mnk)
activity [26]. The reduced activity of eIF4E can selectively down-regulate the translation of mRNA
encoding IκBα, an inhibitor of NF-κB [45]. Although reduced eIF4E phosphorylation causes enhanced
production of interferon beta [45], in the present study the treatment with CDKI-73 reduced the amount
of intracellular antimicrobial peptide Drs in Drosophila fat body tissues and the pro-inflammatory
cytokines IL-6 and TNFα in LPS-stimulated THP-1 macrophages. This supported previous findings
showing that reduced eIF4E phosphorylation has an impact on the translation efficiency of mRNAs,
including mRNAs that encode TNFα, IL-6 and chemokines, in LPS-stimulated IL-1 receptor-associated
kinase 2-deficient mice [46]. Although CDKI-73 treatment did not reduce the amount of secreted
IL-1β by THP-1 macrophages, the treatment of LPS-stimulated macrophages with CDKI-73 led to a
decrease in the secretion of IL-6 and TNFα. To further explore the effect of CDKI-73 treatment on
immune response, future work needs to be focused on the analysis of a wider range of pro- and
anti-inflammatory cytokines secreted by the macrophages. Moreover, future studies will be required
to measure mRNA levels of these pro-inflammatory cytokines after CDKI-73 treatment.
Rab4/Rab11 recycling endosomes represent a critical point for cargo compartmentalisation and a
potential point for divergence in the intracellular traffic of immune mediators [4,5]. The morphological
changes to Rab11 endosomes caused by CDKI-73 treatment altered sorting and compartmentalisation
of immune cargo in recycling endosomes, and therefore disrupted down-stream traffic in the secretory
pathway. CDKI-73 treatment had no discernible inhibitory effect on the secretion of IL-1β and IL-8, and
therefore their intracellular localisation needs to be determined in order to support a Rab11-dependent
mechanism. In this study, CDKI-73 not only inhibited the delivery of Rab11 vesicles to the plasma
membrane, but also resulted in the accumulation of large multivesicular Rab11 endosomes at the
cell periphery. Interestingly, treatment of fat body tissues with CDKI-73 to some extent mimicked
Chédiak-Higashi syndrome at the morphological level. Depletion of Drosophila lyst gene produced a
similar vesicular phenotype, causing a reduced number of small Rab11 vesicles at the plasma membrane
and accumulation of large multivesicular Rab11 endosomes in fat body cells. lystRNAi also resulted in
the accumulation of Drs cargo in these enlarged Rab11 endosomes, whereas CDKI-73 depleted the
amount of Drs detected in immune cells. Despite the similarities, it is yet to be investigated whether
these phenotypes are caused by similar alterations in endosomal dynamics. Given the normal level of
mRNA, this suggested that CDKI-73 might be causing Drs immune cargo to be targeted for degradation,
and this is yet to be determined using inhibitors. CDKI-73 caused an increase in the frequency of
Rab11 endosome fusion events and this might have disrupted the formation of multivesicular Rab11
endosomes, altering immune sorting and directing cargo towards a lysosomal degradative pathway.
The effects of CDKI-73 on endosome morphology did not appear to be due to direct targeting of CDK9,
as the specific inhibitor DRB had a different effect, reducing the size of Rab11 endosomes. Future
studies will be required to determine the mechanism of action, and possible off-targets interactions
and toxicities of the CDKI-73 compound.
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In addition to the effect on recycling endosome morphology, CDKI-73 impacted on Rab11 vesicle
delivery towards the plasma membrane and reduced the secretion of antimicrobial peptide Drs, IL-6
and TNFα. CDKI-73 therefore appeared to have a dual role in the Mnk/eIF4E axis and endosomal
trafficking pathways. We speculate that CDKI-73 may negatively regulate Rab4 and/or Rab11 activity.
This would be consistent with our previous observations on pkaap depletion, which caused similar
alterations in the endosomal morphology and Rab11-mediated trafficking [16]. Alternatively, CDKI-73
may indirectly target other key Rab proteins. Consequently, our findings highlight the need to further
investigate the role of CDKI-73 in the regulation of innate immune secretion. Nevertheless, our study
indicates that CDKI-73 not only limits cargo delivery, but also controls the amount of IL-6 and TNFα in
the cells, giving rise to effective control over innate immune secretion.
5. Conclusions
CDKI-73 alters the secretion of the antimicrobial peptide Drs and pro-inflammatory cytokines
IL-6 and TNFα. This not only involved reduced Rab11 vesicle delivery and cargo exocytosis from
the plasma membrane, but also altered packaging and sorting in Rab11 recycling endosomes. The
effect of CDKI-73 on Rab11 endosome morphology appeared to correlate with reduced amounts
of antimicrobial peptide Drs, but not its gene expression, suggesting that the disruption to Rab11
endosomes might have directed this immune cargo for degradation. The dual effect of CDKI-73 on
immune cargo packaging, sorting and Rab11 vesicle delivery to the plasma membrane provides a new
way of regulating innate immune secretion to control inflammation.
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TNFα co-localise with Rab11 endosomes in LPS-stimulated THP-1 macrophages.
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